Researchers identify the Asah1 gene as a promising target for novel therapies to treat nonalcoholic fatty liver disease ...

Duodenal mucosal resurfacing offers an innovative, minimally invasive approach to managing type 2 diabetes and metabolic ...

The lack of approved pharmacological treatments specifically for NASH with fibrosis represents a significant unmet medical need. In this study, we emphasized the significant role of Asah1 in NAFLD ...

New York City’s Mount Sinai has become the first hospital in the US to perform a deep brain stimulation (DBS) implantation ...

NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic ...

Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant ...

Tryanski said that as a CCBHC, there are certain community treatments that Bert Nash is mandated by the federal government and by the state to provide. Tryanski said that “part of the ...

He believes that NASH treatment is destined to progress rapidly towards combination treatment, just as hep C has, and that these doctors “wrote the book” on how to combine two unapproved ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

A group of state lawmakers and a Macomb County official want stricter limits than the state proposes for Oakland County's ...

The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...